Proteomic Analysis of Amniotic Fluid to Predict Postnatal Renal Function in Fetuses With Renal and Urinary Tract Malformations

Recruiting now · Not applicable

Conditions studied: Kidney Diseases

In brief

The aim of this project is to validate a previously established amniotic fluid 98 peptide signature predictive of post-natal outcome in fetuses with congenital anomalies of the kidney and the urinary tract (CAKUT) in a "real" clinical context. It includes the feasibility of collecting, transporting and analyzing the amniotic fluid peptidome from clinical centers all over France and of providing the result in a clinically accepted time-frame. Therefore, this multicenter study will not only allow to determine the added value of such new prenatal test but also to ensure the feasibility of its introduction in the management of CAKUT pregnancies.

Key facts

Study ID

NCT06912490

Run by

University Hospital, Toulouse

People needed

78

Starts

2025-07-18

Expected to finish

2029-12-20

Last updated by the study team

2026-05-04

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• All fetuses with bilateral renal development anomalies with structural changes in the parenchyma, with or without associated urinary tract anomalies;
• Signed informed consent of the mother
• Non-opposition of the father.

You may not qualify if…

• Unilateral abnormality of renal development
• Any pregnancy for which amniocentesis may represent a risk for the fetus or the mother
• Twin pregnancies
• Pregnant woman protected by law (guardianship, curatorship)

Where it is running

• Children Hospital — Toulouse, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.